JAK VPs banner

JAK Inhibitors Video Perspectives

Healio spoke with expert rheumatologists about JAK inhibitors, including recent advancements, highlights from ACR 2020, how to decide between JAK inhibitors for different patients, areas of future research and more.

Vivian P. Bykerk, MD, FRCPC

In this video, Vivian P. Bykerk, MD, FRCPC, rheumatologist and director of the Inflammatory Arthritis Center of Excellence at Hospital for Special Surgery, and professor of medicine at Weill Cornell University, discussed:

  • safety and efficacy data on JAK inhibitors presented at ACR 2020;
  • her position on JAK inhibitors vs. biologics if a patient has methotrexate inadequate response (MTXIR);
  • deciding between JAK inhibitors for different patients, particularly in the COVID-19 pandemic when it’s important to get patients off of steroids; and
  • areas of future research, such as combining a JAK inhibitor with a biologic, developing agents that can safely inhibit more than one pathway and advancing precision medicine approaches.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.